JP2019535788A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019535788A5 JP2019535788A5 JP2019528512A JP2019528512A JP2019535788A5 JP 2019535788 A5 JP2019535788 A5 JP 2019535788A5 JP 2019528512 A JP2019528512 A JP 2019528512A JP 2019528512 A JP2019528512 A JP 2019528512A JP 2019535788 A5 JP2019535788 A5 JP 2019535788A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- group
- halo
- haloalkyl
- alkoxy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000000217 alkyl group Chemical group 0.000 claims 28
- 125000001424 substituent group Chemical group 0.000 claims 13
- 125000001475 halogen functional group Chemical group 0.000 claims 10
- 125000003545 alkoxy group Chemical group 0.000 claims 9
- 150000001875 compounds Chemical class 0.000 claims 9
- 125000001188 haloalkyl group Chemical group 0.000 claims 9
- 150000003839 salts Chemical class 0.000 claims 9
- 125000004438 haloalkoxy group Chemical group 0.000 claims 8
- 125000004093 cyano group Chemical group *C#N 0.000 claims 7
- 125000000753 cycloalkyl group Chemical group 0.000 claims 7
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 4
- KPCZJLGGXRGYIE-UHFFFAOYSA-N [C]1=CC=CN=C1 Chemical group [C]1=CC=CN=C1 KPCZJLGGXRGYIE-UHFFFAOYSA-N 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 229910052739 hydrogen Inorganic materials 0.000 claims 3
- 239000001257 hydrogen Substances 0.000 claims 3
- 125000003386 piperidinyl group Chemical group 0.000 claims 3
- 125000004528 pyrimidin-5-yl group Chemical group N1=CN=CC(=C1)* 0.000 claims 3
- 125000001412 tetrahydropyranyl group Chemical group 0.000 claims 3
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 claims 2
- 208000024827 Alzheimer disease Diseases 0.000 claims 2
- 201000011240 Frontotemporal dementia Diseases 0.000 claims 2
- 125000004644 alkyl sulfinyl group Chemical group 0.000 claims 2
- 125000004390 alkyl sulfonyl group Chemical group 0.000 claims 2
- -1 benzodioxolanyl Chemical group 0.000 claims 2
- 125000005879 dioxolanyl group Chemical group 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 150000002431 hydrogen Chemical class 0.000 claims 2
- 125000003566 oxetanyl group Chemical group 0.000 claims 2
- 125000003226 pyrazolyl group Chemical group 0.000 claims 2
- 208000023105 Huntington disease Diseases 0.000 claims 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- 208000000609 Pick Disease of the Brain Diseases 0.000 claims 1
- 208000006011 Stroke Diseases 0.000 claims 1
- 208000030886 Traumatic Brain injury Diseases 0.000 claims 1
- 201000004810 Vascular dementia Diseases 0.000 claims 1
- 125000005073 adamantyl group Chemical group C12(CC3CC(CC(C1)C3)C2)* 0.000 claims 1
- 125000004183 alkoxy alkyl group Chemical group 0.000 claims 1
- 125000002393 azetidinyl group Chemical group 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 230000007850 degeneration Effects 0.000 claims 1
- 125000004663 dialkyl amino group Chemical group 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 125000002883 imidazolyl group Chemical group 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 208000014674 injury Diseases 0.000 claims 1
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 claims 1
- 125000001786 isothiazolyl group Chemical group 0.000 claims 1
- 201000010901 lateral sclerosis Diseases 0.000 claims 1
- 208000030159 metabolic disease Diseases 0.000 claims 1
- 125000002757 morpholinyl group Chemical group 0.000 claims 1
- 208000005264 motor neuron disease Diseases 0.000 claims 1
- 230000003387 muscular Effects 0.000 claims 1
- 125000001624 naphthyl group Chemical group 0.000 claims 1
- 208000015122 neurodegenerative disease Diseases 0.000 claims 1
- 208000033808 peripheral neuropathy Diseases 0.000 claims 1
- 125000004193 piperazinyl group Chemical group 0.000 claims 1
- 201000002212 progressive supranuclear palsy Diseases 0.000 claims 1
- 208000020016 psychiatric disease Diseases 0.000 claims 1
- 125000004307 pyrazin-2-yl group Chemical group [H]C1=C([H])N=C(*)C([H])=N1 0.000 claims 1
- 125000002206 pyridazin-3-yl group Chemical group [H]C1=C([H])C([H])=C(*)N=N1 0.000 claims 1
- 125000004940 pyridazin-4-yl group Chemical group N1=NC=C(C=C1)* 0.000 claims 1
- 125000004076 pyridyl group Chemical group 0.000 claims 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims 1
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 claims 1
- 210000000278 spinal cord Anatomy 0.000 claims 1
- 208000024891 symptom Diseases 0.000 claims 1
- 125000003039 tetrahydroisoquinolinyl group Chemical group C1(NCCC2=CC=CC=C12)* 0.000 claims 1
- 125000001113 thiadiazolyl group Chemical group 0.000 claims 1
- 230000008733 trauma Effects 0.000 claims 1
- 230000009529 traumatic brain injury Effects 0.000 claims 1
- 125000001425 triazolyl group Chemical group 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662426631P | 2016-11-28 | 2016-11-28 | |
| US62/426,631 | 2016-11-28 | ||
| PCT/US2017/063231 WO2018098412A1 (en) | 2016-11-28 | 2017-11-27 | Gsk-3 inhibitors |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2019535788A JP2019535788A (ja) | 2019-12-12 |
| JP2019535788A5 true JP2019535788A5 (enExample) | 2020-11-19 |
| JPWO2018098412A5 JPWO2018098412A5 (enExample) | 2022-03-01 |
| JP7114591B2 JP7114591B2 (ja) | 2022-08-08 |
Family
ID=60655130
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019528512A Active JP7114591B2 (ja) | 2016-11-28 | 2017-11-27 | Ｇｓｋ－３阻害剤 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US10752609B2 (enExample) |
| EP (1) | EP3544613B1 (enExample) |
| JP (1) | JP7114591B2 (enExample) |
| KR (1) | KR102575990B1 (enExample) |
| CN (1) | CN110545817B (enExample) |
| ES (1) | ES2878078T3 (enExample) |
| MA (1) | MA46889A (enExample) |
| WO (1) | WO2018098412A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018098413A1 (en) * | 2016-11-28 | 2018-05-31 | Bristol-Myers Squibb Company | Pyrimidine carboxamides as gsk-3 inhibitors |
| MA54546A (fr) * | 2018-12-20 | 2022-03-30 | Amgen Inc | Amides d'hétéroaryle utiles en tant qu'inhibiteurs de kif18a |
| JP7676308B2 (ja) | 2018-12-20 | 2025-05-14 | アムジエン・インコーポレーテツド | Ｋｉｆ１８ａ阻害剤として有用なヘテロアリールアミド |
| WO2020132651A1 (en) | 2018-12-20 | 2020-06-25 | Amgen Inc. | Kif18a inhibitors |
| AU2020324406A1 (en) | 2019-08-02 | 2022-03-17 | Amgen Inc. | KIF18A inhibitors |
| CN116178281B (zh) * | 2023-04-27 | 2023-07-21 | 中国药科大学 | 一种双功能免疫抑制剂及其制备方法和应用 |
| TW202509014A (zh) * | 2023-05-10 | 2025-03-01 | 美商纜圖藥品公司 | ＧＳＫ３α抑制劑及其使用方法 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE0102438D0 (sv) * | 2001-07-05 | 2001-07-05 | Astrazeneca Ab | New compounds |
| CN101801958B (zh) * | 2007-07-19 | 2014-01-29 | 默沙东公司 | 作为蛋白质激酶抑制剂的杂环酰胺化合物 |
| WO2012024179A1 (en) * | 2010-08-18 | 2012-02-23 | Merck Sharp & Dohme Corp. | Substituted amide derivatives as dgat-1 inhibitors |
| SG11201603209XA (en) * | 2013-11-06 | 2016-05-30 | Bristol Myers Squibb Co | Gsk-3 inhibitors |
| AU2014347026A1 (en) * | 2013-11-06 | 2016-06-23 | Bristol-Myers Squibb Company | Substituted pyridine derivatives useful as GSK-3 inhibitors |
| WO2016144797A1 (en) * | 2015-03-06 | 2016-09-15 | Alpharmagen, Llc | Alpha 7 nicotinic acetylcholine receptor allosteric modulators, their derivatives and uses thereof |
| WO2018098413A1 (en) * | 2016-11-28 | 2018-05-31 | Bristol-Myers Squibb Company | Pyrimidine carboxamides as gsk-3 inhibitors |
-
2017
- 2017-11-27 MA MA046889A patent/MA46889A/fr unknown
- 2017-11-27 US US16/463,467 patent/US10752609B2/en active Active
- 2017-11-27 CN CN201780084344.7A patent/CN110545817B/zh active Active
- 2017-11-27 EP EP17812188.5A patent/EP3544613B1/en active Active
- 2017-11-27 JP JP2019528512A patent/JP7114591B2/ja active Active
- 2017-11-27 ES ES17812188T patent/ES2878078T3/es active Active
- 2017-11-27 KR KR1020197018285A patent/KR102575990B1/ko active Active
- 2017-11-27 WO PCT/US2017/063231 patent/WO2018098412A1/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019535788A5 (enExample) | ||
| RU2345070C2 (ru) | Производные аминоиндазолов в качестве лекарственных средств, способ их получения и содержащие их фармацевтические композиции | |
| US9382228B2 (en) | N-acyl-N′-(pyridin-2-yl) ureas and analogs exhibiting anti-cancer and anti-proliferative activities | |
| EP1458383B1 (en) | Heteroaryl substituted pyrazole modulators of metabotropic glutamate receptor-5 | |
| JP4946861B2 (ja) | ヒストンデアセチラーゼ（ｈｄａｃ）の阻害活性を有するヒドロキシアミド化合物 | |
| JP5532366B2 (ja) | ピラジンカルボキサミド化合物 | |
| JP2014507455A5 (enExample) | ||
| JP2009511498A5 (enExample) | ||
| JP2020502092A5 (enExample) | ||
| WO2012009258A3 (en) | Peptidomimetic galanin receptor modulators | |
| CN109071546A (zh) | 作为jak抑制剂的吡唑并[1,5-a]吡嗪-4-基衍生物 | |
| HUP0103366A2 (hu) | Citokin inhibítorként használható amidszármazékok | |
| JP2020517707A5 (enExample) | ||
| JP2015500223A5 (enExample) | ||
| JP2019525939A5 (enExample) | ||
| JP2013525356A5 (enExample) | ||
| NZ771648A (en) | Ectonucleotidase inhibitors and methods of use thereof | |
| JP2019513745A5 (enExample) | ||
| RU2016108038A (ru) | Новые фталазиновые производные и способ их получения | |
| JP2017538753A5 (enExample) | ||
| JP2016534143A5 (enExample) | ||
| WO2020081879A3 (en) | 2,3,5-TRIMETHYL-6-NONYLCYCLOHEXA-2,5-DIENE-1,4-DIONE FOR SUPPRESSING AND TREATING α-SYNUCLEINOPATHIES, TAUOPATHIES, AND OTHER DISORDERS | |
| JP2019536764A5 (enExample) | ||
| TW201920153A (zh) | 具有環狀構造的化合物 | |
| JP2017509676A5 (enExample) |